Big drugmaker Merck (MRK) affirmed Wed. it will present much-anticipated data from its phase 2 C-Swift hepatitis C trial at the American Assn. for the Study of Liver Diseases meeting next month. Investors will have to wait until the meeting to find out the results. Bristol-Myers Squibb (BMY) released top-line data from the phase 3 study of its combo daclatasvir, asunaprevir and BMS-791325 liver disease drug that showed a 93% cure rate in 1st-time cirrhosis patients. Merck shares rose 2.9% to 60.18. Bristol-Myers Squibb rose 0.9% to 50.21.